Organ responses with daratumumab therapy in previously treated AL amyloidosis

Alfred Chung, Gregory P. Kaufman, Surbhi Sidana, Erik Eckhert, Stanley L. Schrier, Richard A. Lafayette, Sally Arai, Ronald M. Witteles, Michaela Liedtke

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing organ dysfunction, including in the heart and kidney. Daratumumab, a CD38-targeted antibody, has recently demonstrated efficacy in producing hematologic responses in previously treated disease. However, data on survival outcomes and organ responses to daratumumab are lacking. Seventy-two patients with previously treated AL amyloidosis who received daratumumab monotherapy with dexamethasone were retrospectively evaluated. With a median follow-up of 27 months, 2-year overall survival (OS) was 86.9% (median OS, not reached) and 2-year time-to-next treatment or death (TTNT)-free survival was 62% (median TTNT, not reached). Forty of 52 evaluable patients achieved a hematologic response (77%), with >60% of patients achieving a very good partial response or better; median time-to-hematologic response was 1 month. Fifty-seven patients (79%) had cardiac involvement, and 55% of evaluable patients achieved a cardiac response, with a median response time of 3.2 months among responders. Cardiac responses were associated with an improvement in OS, with landmark analysis for cardiac responses at 3 months trending toward statistical significance (100% vs 55% at 30 months, P =.051). Forty-seven patients (65%) had renal involvement, and 52% of evaluable patients achieved a renal response, with a median response time of 6 months among responders; there was no significant difference in OS between renal responders and nonresponders. This study demonstrates that daratumumab is highly effective in the treatment of previously treated AL amyloidosis, and a significant proportion of patients can achieve deep hematologic responses, as well as improvements in organ function.

Original languageEnglish (US)
Pages (from-to)458-466
Number of pages9
JournalBlood Advances
Volume4
Issue number3
DOIs
StatePublished - Feb 11 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Organ responses with daratumumab therapy in previously treated AL amyloidosis'. Together they form a unique fingerprint.

Cite this